… among AL patients at SECI and may be of poor prognosis only in B-ALL. Immunophenotyping
may be related to … Both cases expressed CD19 while CD56 was expressed in one patient. …

… prognosis in patients with acute myeloid leukemia and anaplastic large cell lymphoma; however,
its role in DLBCL remains unclear. We report on a patient with CD56-… , prognostic index …

… CD56 bright CD16 − stage to a highly cytotoxic CD56 dim … of CD56 bright and CD56 dim
NK cells are perturbed in ALL. … poor outcome in B/T-ALL patients, independent of prognostic …

… CD56 signaling promotes multiple myeloma growth and adhesion, by activating CREB1 target
… unexplored synthetic lethal approach in CD56-expressing patients with multiple myeloma. …

… Here, we report on a series of 13 patients with high-risk R/R AML, treated with repeated
infusions of double-bright (CD56 bright /CD16 bright ) expanded NK cells at an academic centre …

… 4.8% at diagnosis shows significantly poor prognosis in RFS. … to poor risk, the sum of CD56
bright CD16 − and CD56 bright … intermediate risk to 5.60% in poor risk. These results support …

… It has also been reported to be functionally expressed by myeloid cells, but expression and
… analyzed expression of DNAM-1 in leukemic cells of acute myeloid leukemia (AML) patients…

… by bright CD56, … patients and associated with an extremely poor outcome [23, 24]. Pardo
et al., investigated the relationship between CD56 expression and prognosis in AML patients …

… Clinically CD56-positive AML is characterized by a worse prognosis 1, 3 and a higher
incidence of extramedullary spread including infiltration of the central nervous system. Since …

… is to study the immunohistochemical expression of CD 10 and CD56 in malignant thyroid …
marker in thyroid pathology and whether CD56 can be used to differentiate between follicular …